<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352792</url>
  </required_header>
  <id_info>
    <org_study_id>2.0</org_study_id>
    <nct_id>NCT02352792</nct_id>
  </id_info>
  <brief_title>Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer</brief_title>
  <official_title>Randomized Phase II Study for Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated With Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced suqamous cell carcinoma of the head and neck region receive a
      hypoxia scan either by magnetic resonance tomography, computed tomography or
      fluoromisonidazole (FMISO)-PET-CT. Patients presenting with hypoxia are randomized into
      standard therapy consisting of intensity modulated radiotherapy (IMRT) with 70 Gy plus either
      5-fluorouracil/mitomycin C or cisplatinum (Arm A) or a dose escalation of 10% (77Gy) to the
      hypoxic volume applied via simultaneous integrated boost in addition to the standard
      treatment (Arm B).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to local recurrence</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard plus 10% dose escalation to the hypoxic volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy with 70 Gy</intervention_name>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy with 77 Gy</intervention_name>
    <arm_group_label>dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically verified squamous cell carcinoma of the head and neck region stage III
             and IV eligible for primary radiochemotherapy

          -  measurabel disease by CT and/or MRT and/or FDG-PET-CT

          -  fit for chemotherapy

          -  no prior radiotherapy or major surgery in the head/neck region

          -  Karnofsky Index &gt; 60%

          -  informed consent

        Exclusion Criteria:

          -  uncontrolled secondary cancer

          -  distant metastases

          -  pregnancy

          -  expected malcompliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Welz, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>radiation oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Zips, Prof. Dr. med.</last_name>
    <phone>+49 7071 29 82141</phone>
    <email>daniel.zips@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silke Theden, Mrs.</last_name>
    <phone>+49 7071 29 83420</phone>
    <email>silke.theden@med-uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tuebingen university, radiation oncology</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Welz, Dr. med.</last_name>
      <phone>+49 7071 29 86144</phone>
      <email>stefan.welz@med.uni-tuebigen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Local control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

